Cancer remains the second leading cause of mortality worldwide, with approximately 20 million new cases and9.7 million cancer-related deaths reported in 2022. By 2040, global cancer incidence is projected to reach 29.9million cases annually.
Alberto Avenoza Aznar [0000-0002-5465-3555] +8 more
core
Diagnostic Performance of Galectin-1 and Mucin-1 in Uterine Tumors: A Case-Control Study. [PDF]
Curr Issues Mol BiolKarioti P +9 more
europepmc +1 more source
TMEM59L promotes neuroendocrine differentiation and enzalutamide resistance in prostate cancer by regulating MUC1/β-catenin/MYC axis. [PDF]
Clin Transl MedGuo X +7 more
europepmc +1 more source
The status quo and evolution of glycoconjugates for cancer immunotherapy. [PDF]
Glycoconj JSingh Y, Kamra M.
europepmc +1 more source
Muc1/sec: A Secreted Alternative Splice Variant Of Muc1 That Promotes Tumor Immunity
, 2004 Human MUC1/sec is a secreted form of the glycoprotein mucin 1 (MUC1). In order to characterize the role that MUC1 and MUC1/sec have in tumor progression, these genes were expressed in DA-3 mammary tumor cells.
Grosso, Joseph
core
Structural Basis of a High-Affinity Antibody Binding to Glycoprotein with Glycocalyx Decay. [PDF]
JACS AuBin Han Y +12 more
europepmc +1 more source
Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma. [PDF]
Cancer Immunol ImmunotherPeng Y +8 more
europepmc +1 more source
Immunity to murine breast cancer modified to express MUC1 in transgenic mice tolerant to human MUC1.
, 2001 Immunity to murine breast cancer modified to express MUC1 in transgenic mice tolerant to human ...
Dubravka. Markovic (7979240)
core
An Ocular Surface-Targeting Nucleic Acid Hydrogel for Efficient Dry Eye Disease Treatment. [PDF]
Exploration (Beijing)Liu Y +12 more
europepmc +1 more source